X
[{"orgOrder":0,"company":"AC Immune","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$105.1 million ","upfrontCash":"Undisclosed","newsHeadline":"AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer\u2122 Tau Partnership","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune Advances Phospho-Tau Alzheimer\u2019s Vaccine in Phase 1b\/2a Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AC Immune","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune\u2019s Anti-TDP-43 Antibodies into Clinical Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune\u2019s Alzheimer\u2019s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b\/2a Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"AC Immune","sponsor":"Affiris","pharmaFlowCategory":"D","amount":"$100.8 million","upfrontCash":"$5.0 million","newsHeadline":"AC Immune Acquires AFFiRiS\u2019 Specific Active Immunotherapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to-Moderate Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune ACI-35.030 Phase 1b\/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer\u2019s Vaccine in Highdose Cohort","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Detailed Data From the Phase II Crenezumab Alzheimer\u2019s Prevention Initiative Study in Autosomal Dominant Alzheimer\u2019s Disease Presented at AAIC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune to Present Progress of Alzheimer\u00e2\u20ac\u2122s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune\u2019s Alzheimer\u2019s Disease Vaccine-candidate ACI-35.030 Selected for Further Development","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune\u2019s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer\u2019s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b\/2 ABATE Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"AC Immune","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$418.0 million","upfrontCash":"Undisclosed","newsHeadline":"AC Immune to Regain Global Rights to Crenezumab and Semorinemab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"AC Immune","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by AC Immune
Filters
Companies By Therapeutic Area
Details:
Through the termination, AC Immune will regain all global rights to the anti-amyloid beta antibody RO5490245 (crenezumab) and the anti-Tau antibody semorinemab. Both antibodies have been evaluated in clinical studies for Alzheimer’s disease (AD).
Lead Product(s):
Crenezumab
Therapeutic Area: Neurology
Product Name: RO5490245
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Genentech
Deal Size: $418.0 million
Upfront Cash: Undisclosed
Deal Type: Termination
January 22, 2024
Details:
ACI-35.030 previously named as JNJ-64042056 is the first-in-class anti-pTau vaccine candidate which is being evaluated in phase 1/2 clinical trials for the treatment of Alzheimer’s Disease.
Lead Product(s):
ACI-35.030
Therapeutic Area: Neurology
Product Name: ACI-35.030
Highest Development Status: Phase I/ Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 15, 2023
Details:
ACI-24.060 is designed to enhance the formation of broad-spectrum protective antibodies having the potential to efficiently inhibit plaque formation and increase plaque clearance, which is investigated for the treatment of Alzheimer’s Disease.
Lead Product(s):
ACI-24.060
Therapeutic Area: Neurology
Product Name: ACI-24.060
Highest Development Status: Phase I/ Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Worldwide Clinical Trials
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 27, 2023
Details:
ACI-24.060 is designed to enhance the formation of broad-spectrum protective antibodies having the potential to efficiently inhibit plaque formation and increase plaque clearance, and thereby may reduce or prevent disease progression.
Lead Product(s):
ACI-24.060
Therapeutic Area: Neurology
Product Name: ACI-24.060
Highest Development Status: Phase I/ Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 26, 2023
Details:
Early clinical testing showed that ACI-35.030, a first-in-class anti-pTau vaccine, was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and ePHF species, both of which are closely implicated in AD.
Lead Product(s):
ACI-35.030
Therapeutic Area: Neurology
Product Name: ACI-35.030
Highest Development Status: Phase I/ Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 30, 2022
Details:
MABT5102A (crenezumab) is a passive immunotherapy approach in which patients are treated with monoclonal antibodies that specifically recognize Aβ peptides. This humanized antibody uses an IgG4 backbone.
Lead Product(s):
Crenezumab
Therapeutic Area: Neurology
Product Name: MABT5102A
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 23, 2022
Details:
As previously reported, numerical differences favoring MABT5102A (crenezumab) over placebo were confirmed across the co-primary, multiple secondary and exploratory endpoints, none statistically significant.
Lead Product(s):
Crenezumab
Therapeutic Area: Neurology
Product Name: MABT5102A
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Genentech
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 02, 2022
Details:
Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030, a first-in-class tau vaccine candidate in participants with early Alzheimer’s disease treatment.
Lead Product(s):
ACI-35.030
Therapeutic Area: Neurology
Product Name: ACI-35.030
Highest Development Status: Phase I/ Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 15, 2022
Details:
Semorinemab (RG6100), an anti-tau monoclonal antibody that targets extracellular tau in the brain, is being evaluated for the potential treatment of Alzheimer's disease (AD).
Lead Product(s):
Semorinemab
Therapeutic Area: Neurology
Product Name: MTAU9937A
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Genentech
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 10, 2021
Details:
AC Immune is acquiring AFFiRiS’ anti-alpha-synuclein programs (PD01) targeting neurodegenerative diseases caused by misfolded forms of human self-proteins. All acquired programs are based on AFFiRiS´ AFFITOME® technology.
Lead Product(s):
PD01
Therapeutic Area: Neurology
Product Name: PD01
Highest Development Status: Phase I
Product Type: Vaccine
Recipient:
Affiris
Deal Size: $100.8 million
Upfront Cash: $5.0 million
Deal Type: Acquisition
July 27, 2021